SUBSCRIBE
SUBSCRIBE
News   Drug Development

Roche Avastin Misses Endpoint in Pancreatic Cancer Study

November 13, 2007 | 
1 min read

ZURICH, Nov 13 (Reuters) - Roche on Tuesday said a late-stage study of its cancer drug Avastin in combination with gemcitabine chemotherapy and Tarceva for pancreatic cancer did not meet the primary endpoint for survival.

Clinical research Phase III Europe
Roche
MORE ON THIS TOPIC
3D illustration of an RNA molecule
Cardiovascular disease
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Weigh scales on pink background, top view with space for text. Overweight concept
Weight loss
Kallyope Discreetly Drops Disappointing Data for Oral Obesity Candidate
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Gothenburg, Sweden – April 17, 2020: AstraZeneca in Gothenburg is one of three strategic global R&D centres in medicine. A big sign with the company logotype just outside the entrance.
Cancer
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
February 26, 2025
 · 
1 min read
 · 
Dan Samorodnitsky